Arch Therapeutics (LTS:0HHJ) Stock Based Compensation: $0.07 Mil (TTM As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HHJ Arch Therapeutics Inc LTS:0HHJ
12 GF Score
Price $0.18
View Full Analysis

What is Arch Therapeutics Stock Based Compensation?

Arch Therapeutics LTS:0HHJ 12 Stock Based Compensation is $0.07 Mil as of Jun. 2024. GuruFocus rates LTS:0HHJ with a GF Score™ of 12/100.

Arch Therapeutics's Stock Based Compensation for the three months ended in Jun. 2024 was $0.01 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 was $0.07 Mil.

Arch Therapeutics Stock Based Compensation Related Terms

Arch Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Stock Based Compensation Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.18 0.90 0.50 0.50 0.25

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.03 0.00 0.01
LTS:0HHJ
12GF Score
Arch Therapeutics Inc LTS:0HHJ
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.

What does a Stock Based Compensation of $0.07 Mil mean?
Arch Therapeutics (LTS:0HHJ) has a Stock Based Compensation of $0.07 Mil as of Jun. 2024. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Arch Therapeutics and its competitors.
Is Arch Therapeutics' Stock Based Compensation too high?
Arch Therapeutics' current Stock Based Compensation is $0.07 Mil. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Stock Based Compensation compare to GRTSQ and MTEM?
Arch Therapeutics' Stock Based Compensation of $0.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Arch Therapeutics and its competitors. Arch Therapeutics's current Stock Based Compensation is $0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (LTS:0HHJ) has a current Stock Based Compensation of $0.07 Mil. The current Stock Based Compensation is $0.07 Mil. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Arch Therapeutics (LTS:0HHJ), the current Stock Based Compensation is $0.07 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for LTS:0HHJ

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price